Xvivo Perfusion AB ( (XVIPF) ) has released its Q2 earnings. Here is a breakdown of the information Xvivo Perfusion AB presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
XVIVO Perfusion AB, a leading MedTech company based in Gothenburg, Sweden, specializes in developing innovative technologies for organ preservation and transplantation, aiming to address the global organ shortage crisis. The company’s interim report for the first half of 2025 reveals mixed financial results, with net sales remaining flat at SEK 396.9 million compared to the previous year, and a slight organic growth of 1% in local currencies. The Abdominal business area showed strong growth, while the Thoracic and Services segments experienced declines. Key financial metrics indicate a decrease in operating income and EBITDA margins, attributed to a temporary slowdown in lung transplant activity and increased investments in R&D and working capital. Despite these challenges, XVIVO achieved significant milestones, including FDA approvals for its heart and liver technologies, and continued expansion in key markets. Looking ahead, XVIVO remains optimistic about future growth, focusing on expanding its market presence and launching new technologies in Europe and North America, while continuing to invest in R&D and strategic initiatives to enhance its competitive position in the organ transplantation sector.